Αρχική World News Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated... World News Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC Από Ogkologos - 31 Αυγούστου, 2026 169 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the third pre-specified interim analysis of the OlympiA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Pioneer in Autism Diagnosis And Treatment Dies At 97 21 Σεπτεμβρίου, 2021 Επικοινωνία 18 Ιανουαρίου, 2019 EMA Recommends a Change to the Terms of the Marketing Authorisation... 23 Οκτωβρίου, 2025 Using Technology to Find Cancers Early and Exercise Improves Sexual Health... 31 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Let’s get to the bottom of it – 7 common cancer... Five Questions With…Sharon. FDA Approves Durvalumab for Muscle Invasive Bladder Cancer FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer